Imatinib and type 2 diabetes

David Dingli, Robert C. Wolf, Adrian Vella

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

Objective: To characterize the effect, if any, of imatinib mesylate, an inhibitor of abl tyrosine kinase used in the treatment of chronic myeloid leukemia, on type 2 diabetes. Methods: The centralized pharmacy database was used to identify all patients who had received imatinib at the Mayo Clinic in Rochester, Minnesota, during a 5-year period. The electronic medical records were subsequently reviewed to identify which of these patients had type 2 diabetes. In addition, relevant biochemical data, prior to, during, and after imatinib treatment, were abstracted from the electronic laboratory database and medical records. Results: At the Mayo Clinic in Rochester, Minnesota, a total of 164 patients received imatinib during the period of study (1999 to 2004). Of these 164 patients, 7 had preexisting type 2 diabetes, and diabetes developed in 2 patients during treatment with imatinib. Despite 2 previous reports of improvement in glycemic control with use of imatinib in patients with type 2 diabetes, no net effect on glycemic control or diabetes therapy was noted in our study cohort. Conclusion: On the basis of our current study, it seems unlikely that imatinib substantially affects glycemic control in patients with type 2 diabetes.

Original languageEnglish (US)
Pages (from-to)126-130
Number of pages5
JournalEndocrine Practice
Volume13
Issue number2
DOIs
StatePublished - 2007

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Imatinib and type 2 diabetes'. Together they form a unique fingerprint.

  • Cite this